GLP-1 Medications in Insurance Claims: Ozempic and Mounjaro Risk Management
Understanding GLP-1 agonists in insurance claims, off-label use patterns, safety concerns, and medication review strategy for insurers.
Published: 3 April 2026 | Updated: 3 April 2026
Why GLP-1 Medications Are Emerging in Your Claims
GLP-1 receptor agonists (semaglutide, tirzepatide) have emerged as high-profile medications in your claims portfolio, driven by viral social media marketing around weight loss and metabolic health. Claimants with injuries involving obesity or metabolic dysfunction are increasingly requesting GLP-1 use, often off-label for weight management rather than diabetes control. For your organisation, this represents a new medication-management challenge: understanding emerging therapeutic use, assessing evidence appropriateness in insurance context, and managing off-label prescribing expectations.
This article equips you with practical knowledge of GLP-1 pharmacology, evidence base for specific indications, safety concerns relevant to claims, and triggers for medication review.
GLP-1 Receptor Agonists: Mechanism and Approved Indications
GLP-1 (glucagon-like peptide-1) receptor agonists enhance endogenous GLP-1 signalling, improving insulin secretion, reducing glucagon, slowing gastric emptying, and promoting satiety. Approved indications include type 2 diabetes (semaglutide, dulaglutide, tirzepatide) and obesity management (semaglutide under the brand Wegovy; tirzepatide under the brand Zepbound). In your claims, claimants typically request GLP-1 for weight management in context of obesity-related joint pain, mobility limitations, or metabolic dysfunction secondary to injury.
The distinction is critical: GLP-1 as diabetes management is evidence-supported for appropriate indication; GLP-1 for weight loss alone (off-label or via approved obesity brands) is emerging therapeutic use with evidence in specific populations, but substantial questions remain about long-term efficacy, safety, and cost-effectiveness in claims context.
Approved Indications and Off-Label Use in Claims
In Australia, semaglutide is approved for type 2 diabetes and obesity management. Tirzepatide is approved for type 2 diabetes and obesity. In your claims, understand which indication is being pursued: if a claimant has documented type 2 diabetes, GLP-1 is evidence-supported first-line or second-line therapy. If the indication is weight loss for obesity without diabetes, the evidence base is newer and the off-label status is relevant to your funding decision.
For insurance claims involving claimants with obesity secondary to injury (reduced mobility, deconditioning), the question is whether GLP-1 represents justified pharmacotherapy or whether weight management should be addressed through physical rehabilitation, nutritional intervention, and lifestyle modification first.
Efficacy for Weight Loss and Metabolic Outcomes
GLP-1 agonists produce substantial weight loss in clinical trials: 10 to 15 kg average over 12 to 16 weeks with newer formulations. In individuals with obesity and comorbid diabetes, GLP-1 improves glycaemic control and metabolic risk factors. The effects are genuine and clinically significant. However, weight loss plateaus typically at 6 to 12 months; cessation results in weight rebound over subsequent months to years.
For your claims, the critical question is: does weight loss from GLP-1 translate into improved functional capacity and return-to-work? Some claimants with obesity-related joint pain do improve function with weight reduction; others remain functionally impaired despite weight loss due to underlying pain, deconditioning, or psychological factors. A medication review can help clarify functional outcomes from GLP-1 use.
Adverse Effects and Safety Concerns
GLP-1 agonists produce significant gastrointestinal adverse effects: nausea, vomiting, constipation, diarrhoea. These are dose-dependent and often attenuate with time, but substantial minorities of users experience persistent GI effects that limit tolerability. Additionally, GLP-1 slowing of gastric emptying can cause gastroparesis-like symptoms; there are case reports of acute pancreatitis and gallbladder complications.
Importantly, rapid weight loss from GLP-1 can unmask underlying orthostatic hypotension or exacerbate existing cardiac arrhythmias. In claimants with pre-existing cardiac disease, careful monitoring is required. Additionally, significant weight loss can affect medication metabolism; claimants on narrow-window drugs (anticoagulants, cardiac agents) may require dose adjustments as weight changes.
| Adverse Effect | Frequency | Impact on Claims | Management |
|---|---|---|---|
| Nausea, vomiting | Common (20-40%) | Affects nutrition intake, function; usually attenuates over 4-8 weeks | Dose titration; dietary modification; assess persistence |
| Constipation/diarrhoea | Common (15-30%) | Affects quality of life; may require laxatives or dietary intervention | Fibre, hydration, laxatives; assess persistence |
| Gastroparesis-like symptoms | Uncommon but significant (1-5%) | Severe GI dysfunction; impairs nutrition and work capacity | Dose reduction or cessation; gastroprotective agents |
| Acute pancreatitis | Rare (reports in literature) | Life-threatening if occurs; requires urgent intervention | Cessation; acute care; discontinuation likely |
| Rapid weight loss complications | Depends on cardiac/metabolic status | Orthostatic hypotension; arrhythmia risk in susceptible individuals | Cardiac monitoring; medication adjustment as weight changes |
When to Refer for a Medication Review
GLP-1 use in your claims warrants medication review in several scenarios:
- Initial GLP-1 prescription for weight loss (off-label, not diabetes); assess indication appropriateness and alternative approaches.
- GLP-1 use beyond 12 weeks without documented functional improvement in mobility, pain, or work capacity.
- Significant GI adverse effects (nausea, vomiting, diarrhoea) affecting nutrition or quality of life.
- Signs of gastroparesis (severe GI symptoms, vomiting) emerging during use.
- Claimant on narrow-window medications (anticoagulants, cardiac agents) requiring dose adjustment as weight changes.
- Return-to-work milestone approaching; assess whether GLP-1 is supporting or impeding functional recovery.
- Cessation or dose reduction planned; monitor for weight rebound and metabolic changes.
Medication Review Workflow: GLP-1 Agonists
Step 1: Indication Verification Pharmacist confirms indication (diabetes vs. obesity vs. weight loss); assesses whether off-label use justified by specific claim circumstances.
Step 2: Baseline and Functional Assessment Document baseline weight, BMI, functional capacity (pain, mobility, work status) to establish comparison for outcome assessment.
Step 3: Tolerability and Adverse Effects Evaluate GI adverse effects, cardiac symptoms, or other safety concerns; assess impact on quality of life and function.
Step 4: Functional Outcome Documentation After 8 to 12 weeks, assess whether GLP-1 has resulted in measurable improvement in pain, mobility, function, or return-to-work progress.
Step 5: Recommendation Continue if functional benefit documented and adverse effects tolerable, or consider deprescribing or alternative weight management approach if benefit absent.
GLP-1 and Return-to-Work Considerations
GLP-1 does not directly impair cognition or work capacity (unlike benzodiazepines or opioids). However, gastrointestinal side effects can affect work readiness, particularly in occupations requiring extended periods without access to bathroom facilities or requiring physical exertion. Rapid weight loss can affect energy levels and exercise tolerance transiently. For claimants approaching return-to-work, medication review can assess whether GLP-1 adverse effects are compatible with work demands.
Additionally, meaningful functional improvement from weight loss (if it occurs) should support return-to-work readiness; absence of functional improvement despite weight loss suggests alternative interventions may be needed.
Cost and Accessibility
GLP-1 medications, particularly brand-name versions (Ozempic, Wegovy, Mounjaro, Zepbound), are expensive. Costs range from AUD 100 to 200+ per injection, with weekly or monthly dosing. In Australia, PBS coverage for diabetes is standard, but obesity-specific indications may not be covered. For your organisation, GLP-1 use for weight loss in claims represents direct cost consideration; this should factor into funding decisions, particularly when evidence-based alternatives (physical rehabilitation, nutritional intervention) may be less costly.
Summary and Key Takeaways
GLP-1 medications in your claims represent emerging therapeutic use with genuine efficacy for specific indications but substantial safety and cost considerations:
- GLP-1 agonists are evidence-supported for type 2 diabetes and obesity; off-label weight loss in claims requires careful indication assessment.
- Weight loss from GLP-1 is substantial (10-15 kg) but temporary; cessation results in weight rebound.
- Functional improvement from weight loss is not guaranteed; claimants may achieve weight loss without meaningful gains in pain, mobility, or work capacity.
- GI adverse effects (nausea, vomiting, diarrhoea) are common and may affect quality of life and work readiness.
- Medication review should assess functional outcomes within 8 to 12 weeks; absence of functional improvement despite weight loss suggests GLP-1 alone may be insufficient.
- Cost is substantial; funding decisions should weigh evidence base and functional benefit against cost.
Are GLP-1 medications appropriately managed in your claims?
IMM's medication review specialists assess GLP-1 use for indication appropriateness, document functional outcomes, manage adverse effects, and help clarify whether weight loss is translating into meaningful recovery. We support informed insurer decisions about GLP-1 funding, ensuring treatment aligns with functional recovery goals and cost-effectiveness.
Request a Medication Review
